Cracking KRAS: A $16M Bet Aims to Rewrite Pancreatic Cancer's Future

CAMBRIDGE, MA – June 29, 2026 – In the high-stakes world of oncology, capital follows breakthroughs. Today, a significant $16 million investment signals a major strategic pivot in the war against pancreatic cancer, one of medicine's most formidable adversaries. Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, have announced a joint initiative to fund the next crucial phase of research into KRAS-mutated pancreatic cancer, a genetic flaw present in over 90% of cases.

This is not just another research grant. It is a calculated maneuver designed to build upon a recent, landscape-altering drug trial and unlock the next generation of treatment. By uniting six of the world's most prestigious cancer centers, this investment aims to deconstruct the very mechanisms of treatment resistance and assemble a new arsenal of combination therapies. The move telegraphs a clear signal to the market: the era of single-agent hope is evolving into a sophisticated, multi-pronged assault.

The 'Undruggable' Target is Now in the Crosshairs

For decades, the KRAS gene was the Mount Everest of oncology—a peak that was widely considered unconquerable. As a master regulator of cell growth, its mutated form acts like a stuck accelerator, driving relentless tumor proliferation. The protein's smooth, featureless surface lacked the typical pockets and grooves that drug developers use to anchor therapeutic molecules, earning it the notorious label of 'undruggable.'

That paradigm began to shatter in recent years. The 2021 approval of the first KRAS-targeted therapy for a subset of lung cancer patients proved the concept was possible, igniting a firestorm of research and development. However, that initial breakthrough targeted a mutation rare in pancreatic cancer. The real challenge remained: how to attack the specific KRAS mutations that drive the vast majority of pancreatic tumors.

This new initiative is centered on the success of a new class of drugs known as RAS(ON) inhibitors, which target the protein in its active state. A prime example is Revolution Medicine's daraxonrasib, an investigational drug that has produced stunning results. By targeting the active form of KRAS, these drugs can inhibit a broader spectrum of mutations, making them highly relevant for the pancreatic cancer patient population. The once-impenetrable fortress of KRAS is finally showing cracks in its walls, and this new funding is designed to pour through the breach.

Building on a Breakthrough

The timing of this $16 million investment is no coincidence. It comes directly on the heels of what many are calling a 'landscape-changing' moment for pancreatic cancer treatment. At the American Society of Clinical Oncology (ASCO) meeting just weeks ago, results from the Phase 3 trial of daraxonrasib (RASILU302) were met with a standing ovation—a rare sight for a disease accustomed to incremental progress.

The trial showed that in patients with previously treated metastatic pancreatic cancer, daraxonrasib nearly doubled overall survival to 13.2 months compared to 6.7 months for standard chemotherapy. This wasn't a minor statistical improvement; it was a fundamental validation that directly targeting KRAS in this disease could dramatically change patient outcomes. It is the kind of powerful signal that reorients an entire field of research.

Crucially, the new initiative builds upon a prescient 2024 study by the 'Conquering KRAS in Pancreatic Cancer TeamLab.' That initial effort created what is now an invaluable asset: an unprecedented biobank of tumor and blood samples collected from patients treated with daraxonrasib. These samples, taken before, during, and after treatment, are a biological Rosetta Stone. They hold the secrets to why some tumors respond and others develop resistance. The new funding will empower researchers to decipher this code, analyzing the samples to identify biomarkers and understand the enemy's adaptive strategies.

The Power of 'Radical Collaboration'

Solving a problem as complex as pancreatic cancer resistance cannot be done in a silo. This is where the operational strategy behind the investment becomes as important as the science itself. The initiative is built on Break Through Cancer's model of 'radical collaboration,' a framework designed to dismantle the institutional barriers that have historically slowed medical progress.

The effort unites a supergroup of research powerhouses: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT's Koch Institute, MD Anderson Cancer Center, and NYU Langone Health's Perlmutter Cancer Center. Instead of competing for grants and prestige, these institutions will function as an integrated team, sharing data, technologies, and insights in real time.

This model is a strategic realignment of the business of science. It involves pre-negotiated frameworks for intellectual property and centralized data platforms to ensure that a discovery at one center is immediately available to all. As Linda Tantawi, CEO of the Lustgarten Foundation, noted, "We must invest in the kind of collaborative science that transforms promising advances into meaningful progress for patients." This collaborative engine is designed to accelerate the feedback loop between the lab and the clinic, turning biological insights from the daraxonrasib samples into actionable new treatment strategies far faster than any single institution could alone.

A Strategic Bet on Combination Therapy

The ultimate goal of this $16 million infusion is to define what comes next. The success of daraxonrasib is the beginning of a new chapter, not the end of the story. History has shown that even the most effective single-agent cancer drugs can eventually be outsmarted by tumor evolution.

"Recent advances in RAS-targeted therapies have opened a new chapter in pancreatic cancer research," said Tyler Jacks, PhD, president of Break Through Cancer. "This initiative is focused on what comes next – understanding how these therapies work in patients, the nature of primary and acquired resistance, and how we can develop treatment strategies that build upon the improvements of RAS-directed therapy alone."

To that end, the funding supports a two-pronged attack. First, the deep analysis of the existing patient samples to map out the molecular pathways of resistance. Second, the establishment of a new clinical study to evaluate the next-generation treatment strategies informed by those discoveries. The central hypothesis is that the greatest opportunity lies not in any single treatment, but in intelligent combinations. By understanding how tumors adapt to KRAS inhibition, researchers can pair RAS-directed therapies with other drugs—such as those targeting parallel signaling pathways or harnessing the immune system—to create a multi-front assault that tumors cannot easily escape. This is a strategic move from a single silver bullet to a coordinated, overwhelming force.